en.Wedoany.com Report on Mar 21st, Clariant Corp. recently announced the expansion of its plant in Clear Lake, Texas, USA, adding a new production line for pharmaceutical-grade polyethylene glycol (PEG) excipients compliant with excipient GMP standards.

The Clear Lake plant is Clariant's first production base in the United States dedicated to pharmaceutical-grade PEG excipients, seen as a crucial step in the company's healthcare development strategy. By establishing regional manufacturing capabilities, Clariant is committed to building a more resilient and responsive supply chain system for pharmaceutical companies.

Following the plant expansion, Clariant will be able to offer shorter lead times, helping customers quickly adapt to market changes, reduce inventory costs, while maintaining price competitiveness. Enhanced supply continuity aids pharmaceutical manufacturers in optimizing production schedules and ensuring regulatory compliance.

"This expansion strengthens our ability to provide reliable local supply, making us a true partner for the North American pharmaceutical industry," said Vaios Barlas, Head of Clariant's Healthcare business. "Beyond increasing capacity, we are fostering faster, more collaborative partnerships by bringing production closer to our customers' operations."

The upgraded operations at the Clear Lake plant strictly adhere to the pharmaceutical industry's quality and safety standards. Excipient GMP compliance ensures the manufacturing processes meet international norms, providing customers with the necessary documentation, traceability, and quality assurance. Clariant's pharmaceutical-grade PEG is registered in relevant pharmacopoeias, features low toxicity, and is suitable for a wide range of applications.